Yan-Wei Zhao1, Zi-Jian Feng. 1. Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Abstract
OBJECTIVE: To compare the safety and immunogenicity between domestic and imported, imported and imported split influenza virus vaccine in Chinese population. METHODS: The published studies during January 1996 and June 2008 on the comparison between split influenza virus vaccine were screened and evaluated. The meta analysis was performed on safety and immunogenicity using fixed model or random model according the heterogeneity of the studies. RESULTS: 12 studies which were all random controlled trials between split vaccine were included. 10 trials were between domestic and imported vaccine, and 2 trials were between imported and imported vaccine. For 10 domestic and imported vaccine trials, the local reaction pooled OR = 0.81, 95% CI (0.59, 1.11); the systemic reaction the pooled OR = 0.78, 95% CI (0.50, 1.03); the H1N1 subtype seroconversion pooled OR = 0.94, 95% CI (0.78, 1.14); the H3N2 subtype seroconversion pooled OR = 1.01, 95% CI (0.87,1.17); the B type seroconversion total OR = 1.35, 95% CI (0.98,1.85). For 2 imported and imported vaccine trials,the local reaction pooled OR = 1.19, 95% CI (0.60, 2.37); the systemic reaction the pooled OR = 1.15, 95% CI (0.71,1.87); the H1N1 subtype seroconversion pooled OR = 1.27, 95% CI (0.37, 4.37); the H3N2 subtype seroconversion pooled OR = 1.29, 95% CI (0.39, 4.33); the B type seroconversion pooled OR = 0.95, 95% CI (0.46, 1.37). CONCLUSIONS: were no statistical difference on the safety and immunogenicity between domestic and imported, imported and imported split influenza vaccine in Chinese population.
OBJECTIVE: To compare the safety and immunogenicity between domestic and imported, imported and imported split influenza virus vaccine in Chinese population. METHODS: The published studies during January 1996 and June 2008 on the comparison between split influenza virus vaccine were screened and evaluated. The meta analysis was performed on safety and immunogenicity using fixed model or random model according the heterogeneity of the studies. RESULTS: 12 studies which were all random controlled trials between split vaccine were included. 10 trials were between domestic and imported vaccine, and 2 trials were between imported and imported vaccine. For 10 domestic and imported vaccine trials, the local reaction pooled OR = 0.81, 95% CI (0.59, 1.11); the systemic reaction the pooled OR = 0.78, 95% CI (0.50, 1.03); the H1N1 subtype seroconversion pooled OR = 0.94, 95% CI (0.78, 1.14); the H3N2 subtype seroconversion pooled OR = 1.01, 95% CI (0.87,1.17); the B type seroconversion total OR = 1.35, 95% CI (0.98,1.85). For 2 imported and imported vaccine trials,the local reaction pooled OR = 1.19, 95% CI (0.60, 2.37); the systemic reaction the pooled OR = 1.15, 95% CI (0.71,1.87); the H1N1 subtype seroconversion pooled OR = 1.27, 95% CI (0.37, 4.37); the H3N2 subtype seroconversion pooled OR = 1.29, 95% CI (0.39, 4.33); the B type seroconversion pooled OR = 0.95, 95% CI (0.46, 1.37). CONCLUSIONS: were no statistical difference on the safety and immunogenicity between domestic and imported, imported and imported split influenza vaccine in Chinese population.